कंपनी का अवलोकन
Lyell Immunopharma, Inc. operates as a clinical-stage cell therapy firm dedicated to developing chimeric antigen receptor (CAR) T-cell product candidates specifically for patients suffering from hematologic malignancies and solid tumors. The company functions within the Healthcare sector and the specialized Biotechnology industry, where it focuses on advanced therapeutic interventions rather than traditional small-molecule drugs. Its current market capitalization stands at $556.38M, while its annual revenue for the trailing twelve months is recorded at $36,000, with no specific employee count disclosed in the available data. These financial figures indicate that the company is in an early-stage development phase characterized by significant capital requirements for research, where the market cap reflects investor valuation of future potential rather than current profit generation, and the minimal revenue highlights the pre-commercial nature of its lead product candidates like rondecabtagene autoleucel.
वित्तीय स्वास्थ्य
The company reported a revenue of $36,000 over the trailing twelve months, yet it posted a net income of $-274,448,000 and an EBITDA of $-186,746,000, revealing a massive disparity between top-line activity and bottom-line profitability. This substantial gap indicates a heavy cost structure driven by clinical trial expenses, R&D investments, and operational overheads that far exceed current sales volume. The free cash flow stands at $-81,467,128, which signifies that the company is burning cash rapidly and lacks immediate financial flexibility to fund operations without external financing or asset monetization. In terms of profitability margins, the gross margin is an exceptional 100.0%, suggesting no cost of goods sold, while the operating margin is a negative -1024633.3% and profit margin is 0.0%, both pointing to severe operational losses relative to the negligible sales base. The company holds $247.22M in cash against $50.99M in debt, resulting in a debt-to-equity ratio of 20.55, which suggests a highly leveraged balance sheet relative to its equity base despite the absolute debt amount being manageable against cash reserves. Liquidity is robust with a current ratio of 5.28, indicating that the company possesses more than five times the current assets needed to cover its short-term liabilities. Return on Equity is -87.0% and Return on Assets is -29.8%, metrics that reveal that management has not yet generated positive returns on the capital deployed, reflecting the high-risk, pre-revenue status typical of clinical-stage biotechnology entities.
मूल्यांकन आकलन
The trailing P/E ratio is not available (N/A) due to negative earnings, while the forward P/E stands at -28.39, implying that the market is pricing in future earnings recovery that is not yet realized by current operations. The price-to-book ratio is 2.04, indicating that the stock trades at a premium of 104% over its book value, a common phenomenon in biotech where intangible assets and clinical potential are valued higher than tangible equity. Alternative valuation metrics show a price-to-sales ratio of 15455.06 and an EV/EBITDA of -1.93, suggesting that traditional multiple-based valuation is ineffective and the stock is priced purely on speculative growth expectations rather than current financial performance. The 52-week price range spans from a low of $7.65 to a high of $45.00, meaning the current trading price sits significantly below the recent peak, reflecting the volatility and risk associated with the company's development pipeline. The beta value is -0.07, an unusual negative figure that suggests the stock's price movements have historically moved inversely to or independently of the broader market, indicating a unique volatility profile that does not correlate with standard market indices.
Growth & Income
The revenue growth year-over-year is -45.5%, while earnings growth is not available (N/A), indicating that the company is currently contracting in terms of sales rather than expanding, which is typical for firms transitioning between clinical phases. Since the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it is not distributing any cash to shareholders and instead retains all resources to fund its costly clinical trials and development programs. The absence of dividend payments and negative revenue growth profile underscores that the company relies entirely on capital markets for funding rather than organic cash generation or shareholder returns. Overall, the growth and income profile is defined by significant negative revenue momentum and a complete reinvestment strategy aimed at achieving product approval and commercialization in the future.